Boston Life Sciences Announces 2005 Annual Meeting of Stockholders.BOSTON -- Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) today announced that the 2005 Annual Meeting of Stockholders will be held on Tuesday, September 13, 2005 at the offices of Wilmer Cutler Pickering Hale and Dorr Wilmer Cutler Pickering Hale and Dorr LLP, which also goes by the shorter market name WilmerHale, is a leading American law firm with major offices in Washington, Boston and New York and smaller offices in Palo Alto, Baltimore, London, Brussels, Beijing, Berlin, Los LLP LLP - Lower Layer Protocol , 60 State Street, Boston, MA 02109 at 10:00am EDT EDT abbr. Eastern Daylight Time EDT Eastern Daylight Time EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York EDT . Stockholders of record at the close of business on August 1, 2005 are entitled to vote at the Annual Meeting. A notice of the Annual Meeting and related proxy materials were mailed to BLSI stockholders. Due to security at the WCPHD offices, it is requested, but not required, that you pre-register for this event. If you plan to attend, please contact Meredith Patin pat·in n. Variant of paten. at 508-497-2360 ext. 239 or by email: mpatin@bostonlifesciences.com by Friday, September 9, 2005. Boston Life Sciences, Inc. (BLSI) is a biotechnology company primarily focused on the research and clinical development of biopharmaceutical products for the diagnosis and treatment of central nervous system, or CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , diseases. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by terminology such as "anticipate," "believe," "could," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertakes any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Our logo, trademarks, and service marks are the property of Boston Life Sciences, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Boston Life Sciences, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion